berotralstsat

oral plasma kallikrein serine protease inhibitor

approved for prevention of HAE attacks

from structure-based drug design

Journal of Medicinal Chemistry

BioCryst, Birmingham, AL, USA

The Biocryst oral plasma kallikrein inhibitor, berotralstat (BCX7353), was recently approved as the first non-steroidal treatment for prevention of hereditary angioedema attacks. The molecule is given orally (150 mg QD) despite having…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.